Investors
Cell2Bio is building a scalable platform for physiologically relevant 3D cell culture, combining a protected coating technology with a recurring consumables business model and expanding application potential across tumor models, organoids and organ-on-chip systems.
Protected platform
International PCT patent application (EU, USA, SWE) supports global commercialization.
Predictive biology
3D models designed to capture cell–cell and cell–matrix interactions.
Scalable consumables
Coated plates and surfaces enable recurring research-use revenue.
External validation
Active evaluations across leading academic and industry-oriented research groups.
Platform extension
Future products in organoid-on-chip and tumor-on-chip applications.
Value inflection
Commercial traction, validated production and expanded applications within 3–5 years.
Why now
Market timing is shifting in favor of higher-fidelity preclinical models. More than 90% of drug candidates fail during development, and late-stage attrition creates demand for predictive, scalable models earlier in discovery.
Regulatory tailwinds
Reduced reliance on animal models increases demand for validated alternatives.
Precision oncology
Patient-derived models are becoming central to personalized treatment research.
AI drug discovery
More candidate molecules require scalable, biologically meaningful test systems.
Organoid adoption
Organoids and organ-on-chip systems are moving into mainstream R&D.
$6.5B
TAM — global 3D cell culture market, 2032E
$4.0–4.4B
US + Europe addressable market, 2032E
$3.0–3.5B
Cell2Bio estimate for target applications, 2032E
Sources: Market.us, 3D Cell Culture Market (Aug. 2024); Cell2Bio estimates based on published regional market shares and target geography, application and end-user segmentation.
Validation to date
Validation is moving from internal proof to external market evidence, with ongoing partner studies across Europe and the US in cancer, gene therapy, organoid and drug-screening workflows.
- 3 scientific peer-reviewed publications
- 2 PhD theses
- >10 international conference contributions
- Patent pending (EU, USA, SWE) — US Patent App. 18/718950
- Stability maintained over 12 months across validated production batches
- Three independent production batches with consistent performance
Commercial roadmap
2027 Q1
Launch RUO product
Convert external evaluations into first research-use orders.
2027 Q3
Scale distribution
Activate channel partners in markets where local access and delivery matter.
2028
Strategic accounts
Pharma, CROs and leading academic labs create credibility and volume.
2029+
Expand applications
Organoid-on-chip and tumor-on-chip products deepen account value.
Financing
First round October 2026, 1–2 MSEK, followed by a next round in October 2027 of approximately 5 MSEK. Capital supports the initial commercial phase, manufacturing scale-up and application expansion.
40%
Commercial launch & sales
First orders, go-to-market, distributor activation.
30%
Manufacturing scale-up
Production capacity, QC and supplier readiness.
30%
Research partnerships & validation
External proof points and co-development.
Talk to us
Request the full investor deck or arrange an introductory call with our CEO.